Kasvu Therapeutics
Small-molecule TrkB neuroplastogens for mental health and neurodegeneration
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Kasvu Therapeutics develops selective small-molecule TrkB positive allosteric modulators designed to promote neuroplasticity without hallucinogenic 5-HT2A activity. Its lead candidate KTX-0141 is advancing through IND/CTA-enabling studies for major depressive disorder, with clinical development planned to begin in the second half of 2027. The company is based on research from the University of Helsinki.
- Website
- kasvutx.com
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- KTX-0141 — Selective TrkB PAM neuroplastogen for major depressive disorder · Other